Imatinib mesylate (imatinib) is a potent inhibitor of the tyrosine kinase activity of ABL, c-kit, platelet-derived growth factor receptor and ABL-related gene (ARG). Selective blocking of the ABL-coded kinase activity provides significant clinical benefits in patients with chronic myelogenous leukemia (CML), 1 and a selective inhibition of c-kit is also effective in patients with gastrointestinal stromal tumor (GIST). Imatinib was approved in Japan for the treatment of CML in November 2001 and for GIST in July 2003. Imatinib is generally well tolerated, and grade 3 and 4 non-hematologic toxicities are uncommon. Severe pulmonary adverse events of grade 3 and 4 were only 0.2 and 1.3% in early chronic phase CML, respectively. However, a considerable number of cases with interstitial lung disease (ILD) or interstitial pneumonia (IP) during imatinib therapy were recently reported spontaneously in Japan. Here, we focused on ILD as a possible adverse event associated with imatinib therapy.
We analyzed the adverse events associated with imatinib therapy in patients with CML or GIST, which physicians had spontaneously reported to Novartis Pharma KK, Tokyo, Japan. As of October 2003, approximately 5000 patients with CML and 500 patients with GIST are estimated to have been given imatinib since its approval in Japan, based on the amount of the drug shipment. Of 3023 adverse events spontaneously reported during imatinib therapy, 39 were cases of ILD, 27 cases of which were analyzed in this study after excluding apparent cases of fluid retention owing to imatinib, infection or lung disease induced by other causes. Chest radiographs and computed tomography (CT) or high-resolution CT images before and after the onset of drug-induced ILD were evaluated. Drugrelated ILD was categorized into six radiological patterns in this study, namely, hypersensitivity reaction (HR) pattern, IP pattern, cryptogenic-organizing pneumonia (COP) pattern, nodular pattern, peribronchovascular bundle (PBVB) pattern and diffuse alveolar damage (DAD) patterns. 2, 3 Of the 27 patients with drug-induced ILD, 17 patients were diagnosed as having chronic phase CML (including one second chronic phase), six accelerated phase CML and four GIST. The number of men/women was 17/10. The median age was 63 years (range: 47-82 years) ( Table 1) . Of these 27 patients, seven were previously treated with interferon-a, 10 with hydroxyurea, two with busulfan, one with ranimustine and one with combination chemotherapy. Twelve were previously untreated. One patient each had previously experienced interferoninduced IP and busulfan lung, respectively, and three had lung tumors (two carcinomata and one hemangioma) in their past histories. The median period until development of ILD was 49 days (range: 10-282 days) and the median daily dose of imatinib was 400 mg (range: 200-600 mg) at the time ILD was diagnosed. There was no clear correlation between the development of ILD and either the dose or duration of imatinib therapy. Dyspnea was noted in 20 patients (Grade 1 (G1): two patients, G2: 11 patients, G3: four patients, G4: three patients) and hypoxia was observed in 16 patients (G2: five patients, G3: nine patients, G4: two patients). The median white blood cell count at the development of ILD was 5600/ml (range: 2300-21 200/ml) in CML and 8000/ml (range: 5180-11 800/ml) in GIST. Eosinophilia developed in five patients and the median number of eosinophils was 314/ml (range: 7-2703/ml). Serum KL-6 was elevated in 16 of 19 patients tested and its median was 1395 U/ ml (range: 157-11 200 U/ml).
Chest radiographs and CT findings revealed HR pattern in eight patients (30%), IP pattern in seven patients (26%), COP pattern in four patients (15%), PBVB pattern in four patients (15%), nodular pattern in three patients (11%), unclassifiable in Figure 1 The findings of each CT pattern of imatinib-induced ILD. The radiological characteristics of each pattern are as follows: (1) HR pattern as diffuse homogeneous or widespread opacity mostly composed of ground-glass attenuation and lacking in traction bronchiectasis and structural distortion; (2) IP pattern as ground-glass attenuation, irregular linear or reticular areas of attenuation with associated bronchiectasis and bronchiolectasis; (3) PBVB pattern as patchy ground-glass opacity predominantly distributed along the bronchovascular bundle; (4) COP pattern as nonsegmental abnormal opacity predominantly composed of consolidation in subpleural or peribronchovascular distribution; (5) nodular pattern as diffuse fine nodular opacity probably distributed along the bronchovascular bundle, sometimes accompanied by patchy ground-glass opacity. Abbreviations: AP, accelerated phase; CML, chronic myelogenous leukemia; COP, cryptogenic-organizing pneumonia; CP, chronic phase; CXR, chest X-ray; GIST, gastrointestinal stromal tumor; HR, hypersensitivity reaction; ILD, interstitial lung disease; IP, interstitial pneumonia; n.p., nothing particular; PBVB, peribronchovascular bundle. a Absolute number of eosinophils4500 ml. b NCI-CTCAE v3.0.
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one patient (3%) and no patients showed DAD pattern (Figure 1) . In general, chest radiograph and CT after imatinib therapy showed diffuse or patchy ground glass opacity, consolidation and/or fine nodular opacity in bilateral lungs. Pre-existing pulmonary disease was detected in 11 (41%) patients (seven chronic IP, one busulfan lung, three pneumectomy, owing to two lung cancer and one hemangioma, and one pleuritis) on the chest radiographs and/or CTs before imatinib therapy, although chronic IP in seven patients was very mild. Transbronchial lung biopsy (TBLB) and/or bronchoalveolar lavage (BAL) was performed in seven patients and video-assisted thoracoscopic surgery (VATS) in one patient. The histopathologic findings of TBLB in five patients were interstitial inflammation and fibrosis with intraluminal-organizing fibrosis (patient 2), the destruction of alveolar septi and mixed intra-alveolar and interstitial fibrosis along with eosinophilic infiltration (patient 7), and alveolitis with lymphocytes, plasma cells, mild hyperplasia of type II pneumocytes and organization (patient 9), respectively. The histopathologic finding of VATS in patient 11, whose chest CT showed nodular pattern, was focal infiltration of lymphocytes, mixed intra-alveolar and interstitial fibrosis. One sample of BAL contained eosinophils, and all three samples of BAL were negative on bacterial culture. Results of drug lymphocyte stimulation tests against imatinib were available in nine patients and were negative in all of them. After ILD developed, imatinib was discontinued in all patients; 19 patients were treated with high-dose corticosteroids, five with moderate-dose corticosteroid and three were untreated. After treatment, ILD resolved completely in seven patients and improved in 16 patients, four patients did not improve and one patient suffered from pulmonary fibrosis. After ILD improved, imatinib was re-administered with a reduced dose (range: 100-400 mg/day) to 11 patients. However, ILD recurred in four patients.
In the radiological characteristics in the present study, eight (30%) patients showed HR pattern, which is characterized by homogeneous opacities that typically have a peripheral and upper lobe distribution, and sometimes associated with small areas of consolidation. Hypersensitivity reaction pattern seems to be as hypersensitivity pneumonitis, as reported in previous articles. 4 However, it is considered that hypersensitivity pneumonitis is an inadequate term for drug-induced ILD because hypersensitivity pneumonitis should be confined to the disease process caused by inhaled antigen. 3 Therefore, we use the term hypersensitive reaction pattern. The eosinophilic infiltration was seen in two patients and their radiographic patterns were COP and IP, respectively, and a peripheral eosinophilia was present in five out of 27 patients (19%). These findings suggested that some of them are likely to involve an immunoallergic mechanism. In more than 40% of patients, chest radiographs before imatinib therapy showed the findings of mild chronic IP or pneumectomy owing to lung tumor in this study, suggesting that imatinib-related ILD is likely to develop in the previously damaged lung. In gefitinib, it has also been reported that IP develops more frequently in the lungs damaged from prior therapies. Most patients improved when imatinib is discontinued and corticosteroid was administered in this study. The prognosis of drug-induced lung injury was related to the severity of lung disease; thus patients with DAD pattern are sometimes fatal. The reason for the good prognosis of imatinibinduced ILD might be because there were no patients with DAD pattern.
So far, five cases with IP associated with imatinib have been reported in the literatures. 4, [5] [6] [7] [8] Two of three cases histologically showed IP with eosinophilia and nonspecific IP (NSIP), and their CT showed IP pattern, and one showed non-specific histologic finding and IP pattern on CT. The fifth patient was not examined histologically and their radiograph showed PBVB pattern. All of them recovered following treatment with corticosteroid. In Japan, drug-induced ILD may develop more frequently with many drugs; on the other hand, there were fewer reports in the western countries. Difference in susceptibility to drug toxicity is likely to relate to the diverse genetic background of individuals.
In conclusion, imatinib-related ILD showed various levels of seriousness, but responded well to corticosteroid treatment. Preexisting pulmonary disease might be a risk factor of imatinibinduced ILD; therefore, the radiographs should be evaluated carefully before initiating imatinib treatment. Based on these findings, a caution regarding possible ILD during imatinib therapy was issued in Japan by the pharmaceutical company in June 2003. Physicians should pay careful attention to clinical symptoms such as unexplained fever, cough and dyspnea during several months after starting imatinib therapy, and should immediately discontinue imatinib treatment and investigate and treat patients for serious ILD with corticosteroids after its proper assessment.
